Part 3: Aggressive B-Cell Non-Hodgkin Lymphoma

Leena Varkey Maramattom, MD

Mazie Froedtert Willms & Sue Froedtert Cancer Fellow, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

Timothy S. Fenske, MD

Associate Professor of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

Question 2

Questions 1–3 are based on the following clinical scenario:
A 62-year-old man has recently been diagnosed with stage IV-A diffuse large B-cell lymphoma (DLBCL).

Which first-line treatment approach would be considered the current standard of care for this patient?

  •  High-dose chemotherapy followed by autologous stem cell transplantation
  •  Radiation therapy to all known sites of disease
  •  RCHOP-14 (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone,
    given on a 14-day cycle) for 6 to 8 cycles
  •  RCHOP-21 for 6 to 8 cycles
  •  The hyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin,
    and dexamethasone) regimen

Updated 7/05/2011 • jdw | Copyright ©2013 Turner White Communications